Poltreg S.A. (PTG.WA)

PLN 40.0

(-7.83%)

EBITDA Summary of Poltreg S.A.

  • Poltreg S.A.'s latest annual EBITDA in 2023 was -11.65 Million PLN , down -1256.51% from previous year.
  • Poltreg S.A.'s latest quarterly EBITDA in 2024 Q2 was -3.85 Million PLN , down -34.02% from previous quarter.
  • Poltreg S.A. reported an annual EBITDA of -843 Thousand PLN in 2022, up 72.45% from previous year.
  • Poltreg S.A. reported an annual EBITDA of -3.12 Million PLN in 2021, down -1338.71% from previous year.
  • Poltreg S.A. reported a quarterly EBITDA of -3.85 Million PLN for 2024 Q2, down -34.02% from previous quarter.
  • Poltreg S.A. reported a quarterly EBITDA of -2.71 Million PLN for 2023 Q2, down -247.06% from previous quarter.

Annual EBITDA Chart of Poltreg S.A. (2023 - 2018)

Historical Annual EBITDA of Poltreg S.A. (2023 - 2018)

Year EBITDA EBITDA Growth
2023 -11.65 Million PLN -1256.51%
2022 -843 Thousand PLN 72.45%
2021 -3.12 Million PLN -1338.71%
2020 -217 Thousand PLN -7.43%
2019 -202 Thousand PLN 74.46%
2018 -791 Thousand PLN 0.0%

Peer EBITDA Comparison of Poltreg S.A.

Name EBITDA EBITDA Difference
Bioceltix S.A. -13.22 Million PLN 11.837%
BIOTON S.A. 43.89 Million PLN 126.56%
Captor Therapeutics Spolka Akcyjna -64.76 Million PLN 81.998%
Mabion S.A. 58.31 Million PLN 119.994%
Molecure S.A. -25.5 Million PLN 54.289%
NanoGroup S.A. -7.87 Million PLN -48.14%
Pharmena S.A. 33.78 Million PLN 134.515%
Pure Biologics Spólka Akcyjna -26.07 Million PLN 55.29%
Ryvu Therapeutics S.A. -81.04 Million PLN 85.614%
Synthaverse S.A. 15.34 Million PLN 175.974%
Urteste S.A. -5.73 Million PLN -103.437%